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ABSTRAcT
Hidradenitis suppurativa (HS) is a difficult disease to treat. Although the pathogenesis of 
this inflammatory skin disease is largely unknown, the important role of the immune system 
has been demonstrated in both experimental and clinical studies. Clinicians are therefore 
increasingly prescribing systemic treatments with immunosuppressive agents, but the more 
traditional systemic retinoids, especially isotretinoin, also remain relatively common therapies. 
In order to provide an overview of all currently available systemic immunosuppressive agents 
and retinoids for the treatment of HS, a systematic search was performed using MEDLINE and 
EMBASE databases. All published papers concerning systemic retinoids or immunosuppressive 
treatment for HS in adults were included. The primary endpoint was the percentage of 
significant responders, moderate responders and non-responders. Other endpoints were the 
relapse rate and adverse events. In total 87 papers were included, comprising 518 patients 
with HS who were treated with systemic retinoids, biologic agents or other immunosuppressive 
agents including colchicine, ciclosporin, dapsone or methotrexate. The highest response rates 
were observed with infliximab, adalimumab and acitretin. Overall, the quality of evidence was 
low and differed between the agents, making direct comparisons difficult. However, based on 
the amount of evidence, infliximab and adalimumab were the most effective agents. Acitretin 
was also effective in HS, although the quality of the evidence was low. The therapeutic 
effect of isotretinoin is questionable. Randomized controlled trials are needed to confirm the 




Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin 
disease characterized by recurrent, painful, deep-seated nodules and abscesses. In an advanced 
stadium sinus tracts are formed, eventually leading to fibrotic scars, dermal contractures and 
induration of the skin.1,2 Lesions typically occur on inverse, apocrine gland-bearing skin, like 
the axillary, inguinal and anogenital regions. Quality of life is greatly impaired in HS.3,4 In 
addition to lifestyle changes, therapeutic options include topical and systemic antibiotics, anti-
androgens,  systemic retinoids, immunosuppressive agents, laser treatment, and surgery.5-7 
Since an effective monotherapy is lacking, it is often required to combine different treatment 
modalities to achieve some improvement. 
Although the pathogenesis of HS is largely unknown, follicular hyperkeratinisation followed 
by follicular occlusion is a primary feature of HS.8-11 Several factors probably contribute to 
these histological changes, including smoking, sweating, obesity and hormonal changes.12 
The important role of the immune system in HS has been underlined in recent studies, where 
several observations have been observed, including involvement of the interleukin (IL)-12/
Th1 IL-23/Th17 pathways, and increased TNF-α in the skin and serum.13-15 In addition, there 
is a deficiency of IL-22 and IL-20 in lesional HS skin leading to decreased antimicrobial protein 
(AMP) levels, making the skin prone to bacterial infection.16
In conclusion, both clinical and experimental studies support the use of anti-inflammatory 
drugs and retinoids in the treatment of HS and several different types of these agents are 
currently available. However, there is no consensus on which agent is most effective for HS. 
Therefore, this review aims (i) to evaluate all existing evidence to date for the use of systemic 
immunosuppressive agents and systemic retinoids in HS and (ii) to assess their current position 
in the treatment of HS.
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PATIENTS AND METHoDS 
Inclusion and exclusion criteria 
Included in the study were all fully published papers that reported on the clinical effects of any 
systemic immunosuppressive agents or systemic retinoids in HS localized at the typical inverse. 
Patients had to be 18 years or older. Studies not exclusively dealing with HS were excluded, 
unless data for HS could be extracted separately. Studies were excluded if insufficient details 
were given on treatment regime in respect of dosing, treatment duration and concomitant 
immunosuppressive medication. There were no language restrictions. 
Types of outcome measures 
The efficacy of treatment was classified for each patient as “significant response”, “moderate 
response” or “nonresponse.” A significant response was defined as a reduction of the Sartorius 
score with ≥50%, improvement in quality of life of >50% or if stated so by the authors. A 
moderate response comprised score reductions <50% or if stated so by the authors. The 
primary endpoint comprised the percentage of significant responders, moderate responders 
and nonresponders. If a study did not report individual results, all patients of that study were 
categorized corresponding to the reported mean results. Dropouts were considered to be 
nonresponders. The secondary endpoint was the percentage of responders that relapsed during 
or after discontinuation of treatment, and the tertiary endpoint comprised adverse events 
(AEs).  
Identification of studies 
Databases were systematically searched by two independent authors (SvH and JLB) for studies 
dated up to May 2012. A search was conducted using EMBASE (search terms: ‘hidradenitis 
suppurativa’/exp OR ‘hidradenitis suppurativa’ OR (hidraden* AND suppurativ*) OR ‘acne 
inversa’ OR ‘inverse acne’) and Medline (search terms: “Hidradenitis Suppurativa”[MeSH] 
OR (hidraden* AND suppurativ*) OR “acne inversa” OR “inverse acne”). Reference lists of 
included papers and relevant reviews were manually searched to identify additional papers.  
Data extraction 
Two authors (JLB and SvH) independently conducted data extraction by using standardized 
forms. Discrepancies between the researchers were resolved through discussion. Authors were 
not contacted for missing data. Data were analysed by means of descriptive statistics. 
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Quality assessment 
The quality of evidence was assessed by grading as follows: A, systematic review or meta-
analysis, randomized controlled trial with consistent findings, or all-or-none observational 
study; B, lower quality clinical trial or study with limitations and inconsistent findings, cohort 




Figure 1 shows the process of study selection, at the end of which 87 papers were included, 
comprising a total of 518 patients. The immunosuppressive therapies evaluated in these 
papers were biologics, colchicine, ciclosporin, methotrexate and dapsone. Treatment with 
systematic retinoids included the use of acitretin and isotretinoin. Two papers dealt with 
two immunosuppressive agents and these studies are therefore discussed in subheadings 
of the Results section.18,19 The level of evidence of included papers is described for each 
immunosuppressive agent in Table 1. A summary of the results is described in Figure 2. 
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Studies: We identified 15 papers studying a total of 68 patients.18-32 One study had a 
randomized double-blind placebo-controlled design (evidence level A).31 In one retrospective 
cohort study, the effectiveness of adalimumab was compared to infliximab (evidence level 
B).19 Four other studies had an evidence level of B,20,21,23,32 and the remaining 9 studies had 
level C.18,22,24-30 Dosing regimes varied from 40-80 mg in a frequency ranging from weekly 
to every other week. The treatment duration was ≥1 year in three studies,21,24,26 ≤6 months 
in six studies18,20,22,27,31,32 and unclear in six studies.19,23,25,28-30 One patient was simultaneously 
to adalimumab treated with methotrexate for the first 2 months.26 The follow-up time varied 
between studies, ranging from 13 weeks-29 months. 
Primary endpoints: in total, 30/68 patients (44%) showed a significant response to 
adalimumab, 24 patients (35%) had a moderate response and 14 patients did not respond 
(21%). (Figure 2) 
Secondary endpoints: one paper reported that the majority of the seven responding patients 
showed recurrence of HS after 1 year of follow-up; however, individual numbers could not be 
extracted.19 Occurrence of relapse was described for 35 of the remaining 42 responders: 22/35 
(66%) relapsed within 3-10 months after discontinuation of treatment.21,23,25,26,28,31 Seven of the 
35 responders (20%) relapsed during treatment, but symptoms improved in all when the dose 
of adalimumab was increased.23,26,28  
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% of non 
responders
Biologicals 66 3 5 17a 24 48b 71
Adalimumab 15 1 7 5 33 9 60 79 21
Etanercept 9 1 11 5 56 3 33 56 44
Infliximab 42 1 2 7 17 34 81 89 11
Ustekinumab 2 2 100 75 25
Retinoids 13 6 46 7 54
Acitretin/etretinate 6 2 33 4 67 95 5
Isotretinoin 7 4 57 3 43 36 64
Other 8 2 25 6 75
Ciclosporin 3 3 100 100 0
Dapsone 3 3 100 100 44
Colchicine 1 1 100 75
Methotrexate 1 1 100 100
a one paper compared adalimumab with infliximab, and is included as level B for both adalimumab and infliximab.19
b One paper describes the efficacy of adalimumab and etanercept; therefore it has been included as level C for both adalimumab and 
etanercept.18
 
Table 1. Level of evidence for all included studies 
Etanercept 
Studies: nine papers comprising 54 patients evaluated the effect of etanercept on HS.18,33-
40 One study had a randomized double-blind placebo controlled design (evidence level A); 
however, after 12 weeks all patients received open-label etanercept.33 We included only those 
10 patients who were initially allocated to etanercept group. Five papers had evidence level 
B34,35,37,39,40 and 3 papers level C.(18,36,38) Dosing schedules varied from 25 mg to 50 mg once or 
twice weekly to 100 mg weekly. Treatment duration was 3 months in two papers,34,35 6 months 
in two33,39 and around 1 year or longer in four papers.18,36-38 The follow up time was 17-144 
weeks. Long term results of the patients described by Giarmellos et al.35 were reported in a 
separate paper.41  
Primary endpoints: a significant response to etanercept was observed in 21/54 patients (39%), 
whereas nine patients (17%) had moderate improvement and 24 patients (44%) did not 
respond to the treatment. (Figure 2) 
Secondary endpoints: in total 18/30 responders (60%) relapsed after treatment was 
discontinued. The time to relapse ranged from immediately after stopping of treatment until 8 
months thereafter, but the majority had recurrence of HS lesions within 2 months.  
Tertiary endpoint: Table 2 describes the tertiary endpoints. One study did not report on AEs.18 
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Infliximab  
Studies: the efficacy of infliximab was evaluated in 42 papers, comprising 147 patients. 
One study had a randomized double-blind placebo controlled design (evidence level A) but 
after 8 weeks all patients received infliximab.42 Only those 15 patients who were initially 
allocated to infliximab were included. Evidence levels B and C were found in seven19,43-48 
and 34 studies49-82 respectively. One study compared the effect of infliximab with another 
treatment, namely adalimumab.19 Almost all 147 patients received intravenous infliximab 
5 mg/kg at weeks 0, 2 and 6. In 10 studies treatment was discontinued after these three 
administrations.19,46,57,61,63,65-67,70,82 However, the majority of patients received maintenance 
therapy every 6-8 weeks. Dosing schedules were not clear in five papers.50,69,71,74,75 The duration 
of treatment was >1 year in nine studies.45,48,49,53,56,60,64,79,80 In four papers patients, in addition to 
infliximab, patients received methotrexate, which might have prevent the formation of auto-
antibodies.45,49,60,64 Simultaneously to infliximab, patients were treated with azathioprine in two 
studies,70,72 prednisolone in one study,77 prednisolone and ciclosporin in one study,68 and with 
oral azathioprine and methylprednisolone in one study.71  
Primary endpoints:  a significant improvement was seen in 74/147 patients (50%); 57 patients 
(39%) showed moderate improvement and 16 patients (11%) had no response (Figure 2) 
Secondary endpoints: Only 10/131 responders (8%) experienced recurrence of HS during 
treatment,48,49,55,60,68,79 and 26 responders  (20%) relapsed within 2 weeks to 3 years after 
discontinuation of therapy.42,46,52-54,57,62,63,67,73,75 One paper reported that the majority of patients 
had recurrence of HS one year after discontinuation of treatment, however, individual numbers 
could not be extracted.19  
Tertiary endpoints: Fourteen studies did not report on AEs.50,52,55,59-61,65,66,69-71,74,78,82 AEs were 
observed in 19 studies (Table 2).19,42-48,57,63,64,68,72,73,75,76,79-81 
Ustekinumab 
Studies: Two papers comprising a total of four patients, evaluated the effect of ustekinumab 
(both evidence level C).83,84 The patients received 45 mg ustekinumab at weeks 0, 4 and 12. 
Subsequently, one patient received injections every 3 months,84 and three patients every 2 
months.83 Three patients were treated for at least 6 months and two of them were probably 
still on treatment at the time the paper was written.83 
Primary endpoints: two of the four patients (50%) showed a significant response, one patient 
had a moderate response (25%) and one patient (25%) did not respond. (Figure. 2) 
Secondary endpoints: one responding patient had temporary relapses every 2 weeks prior to 
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his next injection, but after administration.84 In another responding patient lesions recurred 
after 6 months.83 The dose ustekinumab was therefore increased to 90 mg and his disease has 
improved ever since. The remaining one responding patient did not relapse during treatment.83  
Tertiary endpoint: AEs were reported in one paper (Table 2).83 
Retinoids 
Isotretinoin 
Studies: seven papers evaluated the effect of oral isotretinoin, and comprised a total of 174 
patients. Level B evidence was found in four papers85-88 and level C in three.89-91 The daily 
dosages of isotretinoin were 0.5-1.2 mg/kg and treatment duration was 4-12 months. One 
patient was pretreated with prednisone and erythromycin, followed by the gradual introduction 
of isotretinoin.89  
Primary endpoints: significant improvement was observed in 32/174 patients (18%), moderate 
improvement in 30/174 patients (17%) and no response was observed in 112 patients (64%) 
(Figure 2). 
Secondary endpoints: one study comprising 14 responders did not mention whether 
recurrences occurred after cessation of therapy.85 Of the remaining 48 responders, six patients 
(13%) relapsed within a couple of months after discontinuation of treatment.  
Tertiary endpoint:  Two studies did not report on AEs.85,89 All remaining 18 patients experienced 
AEs (Table 2).   
Acitretin and etretinate 
Studies: Acitretin is a metabolite of etretinate and has replaced treatment with etretinate in a 
variety of disorders, as it has a much shorter elimination half-life and is equally effective. Six 
papers reported on the treatment of HS with these retinoids, and comprised 22 patients.92-97 
The level of evidence was B in two studies;92,96 the remaining papers were level C. Patients 
treated with etretinate received daily doses of 0.35-1.1 mg/kg and the daily doses for acitretin 
ranged from 0.25-0.88 mg/kg. The duration of treatment was 3-39 months. 
Primary endpoints: significant improvement was seen in 16 of 22 patients (73%), five patients 
(23%) improved moderately and one patient (5%) did not respond to the therapy (Fig. 2). 
Secondary endpoints: No relapses during therapy were described. Acitretin or etretinate 
treatment was eventually discontinued in 17 patients. Within six months after cessation of 
therapy, six of 17 patients (35%) had recurrence. Eight patients (47%) relapsed >1 year after 
discontinuation of treatment.  
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Tertiary endpoint: The AEs that were reported are shown in table 2. Two studies did not report 
on AEs.93,97 For one study, data on AEs could not be extracted separately for HS.96  
other therapies 
Dapsone 
Studies: the effect of dapsone was described in three papers all with evidence level C.98-100 
In total 34 patients were treated with doses of 25-200 mg daily during 0.5-48 months. The 
majority of patients was still on treatment at the time of study closure.  
Primary endpoints: A significant improvement was seen in 12/34 patients (35%) showed a 
significant response, seven patients (21%) had a moderate response and 15 patients (44%) did 
not respond (Figure 2). 
Secondary endpoints: Two studies reported that discontinuation of therapy led to a rapid 
recurrence of HS lesions in all patients, and that dapsone treatment could therefore not be 
terminated.99,100 Two out of nine responders in the study of Yazdanyar et al.98 also rapidly 
relapsed after cessation of treatment; however, re-introduction of dapsone led to rapid 
improvement.  
Tertiary endpoint: Adverse events are shown in table 2.  
Colchicin 
Studies: we identified one paper (evidence level B) describing eight patients who were treated 
with colchicine 0.5 mg twice daily during 4 months.101  
Primary endpoints: Two out of eight patients (25%) had a moderate respons and six out of 
eight patients (75%) did not respond to colchicines (Figure 2). 
Secondary endpoints: these were not stated.   




Studies: we identified three papers (evidence level C) on ciclosporin.102-104 Four patients were 
treated with ciclosporin 2-6 mg/kg daily for 4-15 months. Two patients were concomitantly 
treated with prednisolone and oral antibiotics.102,103  
Primary endpoints: a significant response was observed in two of four patients (50%) and the 
remaining two patients had a moderate response (Figure 2). 
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Secondary endpoints: in one patient ciclosporin was discontinued after 4 months, leading to 
a recurrence 4 months later.102 Two patients were still on treatment at the time the paper was 
published and did not experience any relapses. It was not reported whether the last patient 
experienced relapse.104 
Tertiary endpoint: These were not reported in any of the studies. 
Methotrexate 
Studies: we identified one paper that reported on the effectiveness of methotrexate in HS.105 
It concerned an open study in which two patients received a weekly dose of 12.5 mg and one 
patient received 15 mg. Treatment duration was 6 weeks, 4 months or 6 months.  
Primary endpoints: none of the three patients responded to the treatment with methotrexate 
(Figure 2). 
Secondary endpoints: since none of the patients showed a response to the treatment, time to 
relapse was not applicable. 



































 of total num
ber of papers and treated patients for each agent, including response rates.
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Immunosuppressive 
agent (number of  
treated patients)
Observed adverse events (frequency) Nr of patients that 
discontinued treatment 
due to adverse events
Adalimumab (68) Painful injection site,a mild infections (10), non-specific gastrointestinal symptoms 
(3), non-specific rash (3), fatigue (3), elevated liver enzymes (2), reactivation of 
Epstein-Barr virus (1), severe infusion reaction urticaria (1), facial cellulitis (1), 
irritation ears (1), hoarseness (1), headache (1), dry eyes (1), muscle chest pain (1), 
dry skin (1), hay fever (1),
1(23)
Etanercept (54) Injection site reaction,a upper respiratory tract infection (4), nausea (3), paresthesias 
(2), chest pain (2), cellulitis (2), muscle cramps (1), flu-like symptoms (1), 
hypertension (1), elevated cholesterol (1)
3 (34)
Infliximab (147) Non-specific side effects (14), headache (7), acute arthritis/myalgia (8), 
hypersensitivity reactions (5), influenza-like illness (4), dizziness (3), asthenia 
(3), numbness in legs/neuropathy (3), skin rash (3), anaphylactic shock (1), 
pneumococcal sepdis (1), localized tuberculosis infection (1), pustular lesions lower 
limbs (1), fever (1), hypertension (1), herpes zoster (1), colon cancer (1), cervical 
abscess (1), dyspnoea (1), lupus like reaction (1)
31 (43-46,48,57,63,68,72,73,75,76,78-80)
Ustkeinumab (4) Cystitis (1), psoriasiform dermatitis (1), HS lesion infected by staphylococcus aureus 
(1)
None
Isotretinoin (174) Cheilitis/xeorsis (15), usual side efectsb (3), arthralgia (1), headache (1) 10 (86)
Acitretin/etretinate 
(22)
Cheilitis/xerosis (13), alterations in lipids (4), altered triglyceride levels (3), 
hypertrichosis/photosensitivity (2), alopecia (2), depression/fatigue (1), headache (1), 
loss of concentration (1), elevated cholesterol (2), buzzing ears (1), joint pain (1)
2 (92,95)
Dapsone (34) Anemia/hemolysis (4), nausea (3), dizziness (2), tiredness (2), headache (2), elevated 
bilirubine (1), rash (1), gloomy mood (1), malaise (1)
None
Colchicine (4) Nausea (3), diarrhea (3) 1 (101)
Methotrexate (3) Adverse events not stated none
Ciclosporin (4) Adverse events not stated none




To the best of our best knowledge, this is the first systematic review specifically aimed to 
analyze all currently available evidence of immunosuppressive agents and systemic retinoids for 
the treatment of HS. In total 518 patients were analysed, divided over 87 papers. The majority 
of patients (n = 273) was treated with a biological agent. Overall, the quality of the included 
papers was low; only three randomized controlled trials were identified, all on biologics.31,33,42 
The majority of papers were case reports or series, bringing along a risk of publication bias. 
Two papers were not identified by our search strategy due to the fact that they were not 
incorporated in Medline or EMBASE.96,97   
Based on our results, the most effective agents for HS were infliximab, adalimumab and 
acitretin with respectively 89%, 79% and 96% of patients, respectively, responding to 
treatment. However, as the results of acitretin were based on far fewer patients and were of a 
lower level of evidence than the results for infliximab and adalimumab, caution must be taken 
when directly comparing the efficacy of these agents. The positive results of infliximab and 
adalimumab are in accordance with the findings of Van Rappard et al.106 Acitretin for HS is 
barely mentioned in the literature, however, its positive effect is pharmacologically reasonable, 
as the primary event in HS is follicular occlusion and acitretin induces normalization of the 
epithelial cell proliferation and differentiation.107,108 Not surprisingly, isotretinoin is ineffective 
for HS as this agent primarily works on sebaceous glands, which are not involved in the 
pathogenesis of HS.109,110 The observation that 35% of treated patients still responded to 
isotretinoin, is more likely to be due to the immunomodulatory effects of this retinoid.111  
The highest quality of evidence was identified for etanercept, which enables us to conclude 
that the efficacy (56% responders) was relatively low. Only a few patients have been treated 
with ustekinumab, ciclosporin, dapsone, methotrexate and colchicine. It has been shown that 
the IL-12/IL-23 pathway is upregulated in HS, therefore there is a rationale for the efficacy 
of ustekinumab (an inhibitor of this pathway), and the first results of this agent are indeed 
promising.83,84 However, clinical trials are needed to confirm its effect. The same applies for 
ciclosporin; although all patients responded to treatment, this agent has been studied in only 
four patients, making it impossible to draw any definite conclusions. The efficacy of dapsone is 
doubtful, methotrexate as a monotherapy seems of little value and colchicine is not effective in 
HS. 
Although long-term results and relapse rates were not available for many papers on biologics, 
recurrence of HS occurred frequently during therapy or within a couple of months after 
cessation of biologic therapy. In contrast, Boer and Nazary92 achieved long-term remission (i.e. 
>1 year) in a majority of patients treated with acitretin, indicating that this is probably also 
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effective on the long term. However, this observation needs to be confirmed in bigger trials 
since only 12 patients were included. 
Adverse events were observed with all agents, except for ciclosporin and methotrexate, where 
it was not stated. The highest number of withdrawals due to AEs occurred with infliximab and 
isotretinoin. Other reviews also showed that the risk of withdrawal is higher during infliximab 
therapy compared with adalimumab and etanercept therapy.106,112 The most common AE 
during acitretin therapy is cheilitis which can be very disturbing for patients. Moreover, the 
most important disadvantage of acitretin is that it has extremely teratogenic side effects.113 
Therefore, this agent should mainly be reserved for men and sterilized or postmenopausal 
women.  
A limitation of this review, and any other review on HS treatment, is heterogeneity between 
the studies in respect of study design, number of included participants, the severity of HS and 
the timing and methods for outcome assessments. Therefore, caution must be taken in directly 
comparing the different treatment options of HS.  
In conclusion, this review indicates that, based on the evidence today, infliximab and 
adalimumab are the most effective immunosuppressive agents for HS. Additionally, acitretin is 
a promising agent and definitely worth considering in men and sterilized or postmenopausal 
women, although high quality evidence is lacking for its administration in HS. Also, these data 
strongly indicate that there is a need for randomized controlled clinical trials in order to identify 
the most effective treatment targets and the most effective therapy for HS. 
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